Verona Pharma Plc (LON:VRP) reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 100 ($1.40) and last traded at GBX 103.49 ($1.45), with a volume of 18698 shares. The stock had previously closed at GBX 104.50 ($1.47).

Several research analysts have recently commented on the stock. restated a “buy” rating on shares of Verona Pharma in a research note on Tuesday, November 7th. N+1 Singer restated a “buy” rating on shares of Verona Pharma in a research note on Tuesday, November 7th. Finally, Jefferies Group restated a “buy” rating and set a GBX 250 ($3.51) price target on shares of Verona Pharma in a research note on Wednesday, November 8th. Six research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of GBX 130 ($1.82).

In other news, insider David Ebsworth bought 10,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of GBX 107 ($1.50) per share, for a total transaction of £10,700 ($15,002.80).

TRADEMARK VIOLATION WARNING: “Verona Pharma (VRP) Hits New 12-Month Low at $100.00” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/02/09/verona-pharma-vrp-hits-new-12-month-low-at-100-00.html.

About Verona Pharma

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.